The DOI matches its Crossref record; 83 of the 86 references it cites were found in a registry or an index.
Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
Abstract
Therapy targeted against the epidermal growth factor receptor (EGFR) has demonstrated dramatic tumor responses and favorable clinical outcomes in a select group of non-small cell lung cancer (NSCLC) patients whose tumors harbor EGFR activating mutations. The best characterized of the mutations conferring sensitivity to EGFR tyrosine kinase inhibitors (TKIs) are deletions in exon 19 and a point mutation in exon 21 (L858R). Likewise, the most common mutation that confers resistance is the T790M point mutation. However several other mutations have been reported and several have been characterized as regards their role in sensitivity or resistance to EGFR TKIs. Resistance to the EGFR TKIs erlotinib and gefitinib, and the newer irreversible EGFR TKIs is a problem of fundamental importance. Recognition of the presence and significance of specific EGFR mutations is important for appropriate therapeutic implementation of EGFR TKIs and research and development of mutation-specific inhibitors. We summarize the literature and present an overview of the subject of less common EGFR mutations and their clinical significance, with an emphasis on EGFR TKI sensitivity or resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Patients with atypical EGFR mutations show heterogeneous and reduced responses to EGFR inhibitors1,3,7–10, including osimertinib12.”
From Structure-based classification predicts drug response in EGFR-mutant NSCLC (2021) · cites this paper as [8]
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
Shigematsu, H., Lin, L., Takahashi, T., Nomura, M., Suzuki, M., Wistuba, I. I., Fong, K. M., Lee, H., Toyooka, S., Shimizu, N., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji055 · Cited by 2,377
Self-citationScreening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rosell, R., Moran, T., Queralt, C., Porta, R., Cardenal, F., Camps, C., Majem, M., Lopez-Vivanco, G., Isla, D., Provencio, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904554 · Cited by 2,373
High density synthetic oligonucleotide arrays
Lipshutz, R. J., Fodor, S. P. A., Gingeras, T., & Lockhart, D. J. (1999) · Nature Genetics · doi:10.1038/4447 · Cited by 2,204
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor
Zhang, X., Gureasko, J., Shen, K., Cole, P. A., & Kuriyan, J. (2006) · Cell · doi:10.1016/j.cell.2006.05.013 · Cited by 1,650
Flagged first, then by citations
3 of the 86 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- Shih, 2011, Activity of BIBW 2992, an irreversible EGFR/HER1 TKI, in lung adenocarcinoma patients harboring less common EGFR mutations, Ann Oncol, 21, 415
- Horn, 2011, Activity and tolerability of combined EGFR targeting wih afatinib (BIBW 2992) and cetuximab in T790M+ NSCLC patients. J Thorac Oncol, 6, S39
Cited by
Sorted by citations
Items 101–110 of 110
Baek, J. H., Min, Y. J., Cho, E. K., Cho, B. C., Kim, Y. B., Sun, J., Ahn, M., & Park, K. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu349.54
Lacković, L. N., Tadić, L. L., Stanetić, М., Tanasković, N., Marić, S., & Lacković, M. (2019) · Medicinski Glasnik · doi:10.17392/1003-19
US FDA‐Approved Small‐Molecule Kinase Inhibitors for Cancer Therapy
Yu, M., Tadesse, S., & Wang, S. (2021) · Wiley eBooks · doi:10.1002/0471266949.bmc214.pub2
Biology and pathophysiology of central nervous system metastases
Singh, M., Dahal, A., de Sauvage, M. A., Larson, J. M., & Brastianos, P. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-821976-8.00031-1
Prädiktive Testung von Tumorgewebe und ihre klinischen Konsequenzen
Hoffmann, J. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-46764-0_148-1
Lechner, A. C., Rai, A., Rojas‐Rudilla, V., Kuang, Y., Paweletz, C. P., Sholl, L. M., & Dong, F. (2023) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2023-0088-oa
Zhang, H., Liu, C., Wang, S., Wang, Q., Xu, F., Jiang, H., Zhang, Y., Su, X., & Li, G. (2024) · eLife · doi:10.7554/elife.95453.1
Dai-Shinozaki, A., Sakakibara‐Konishi, J., Hatanaka, K. C., Wakabayashi, K., Shinagawa, N., Matsuno, Y., Hatanaka, Y., & Konno, S. (2025) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2025.102249
Rajput, S., Mhaiskar, A., Shah, U. A., & Patil, S. (2026) · Pharmacological Research - Reports · doi:10.1016/j.prerep.2026.100090
Metadata
- Authors
- Massarelli, E., Johnson, F. M., Erickson, H. S., Wistuba, I. I., & Papadimitrakopoulou, V.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Papadimitrakopoulou, Vassiliki
- Venue
- Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 80
- Issue
- 3
- Pages
- 235-241
- ISSN
- 0169-5002 (ISSN-L)
- OpenAlex
- W2014993624
- Cited by
- 110
- References
- 86
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 9 · 2023: 5 · 2022: 16 · 2021: 8 · 2020: 11 · 2019: 9 · 2018: 8 · 2017: 7 · 2016: 8 · 2015: 8 · 2014: 10 · 2013: 4
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Lung Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- EGFR mutation, non-small cell lung cancer, EGFR tyrosine kinase inhibitors, drug resistance, erlotinib, gefitinib, exon 19 deletion, L858R mutation, T790M mutation, targeted therapy
- MeSH terms
- Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Exons, Humans, Point Mutation, Drug Resistance, Neoplasm, Protein Kinase Inhibitors, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
